Evidence map›Paper›PMID 41034872›Full record

ArticleJournal of nanobiotechnology2025

Magnetically navigated nano-PROTAC ameliorates acute lung injury.

Sheng Chen, Enen Chen, Jianfen Su, Yingjie Gong, Shiqi Tang, Aiping Qin, Ao Shen, Shunqing Tang, Lingmin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sheng Chen *The Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China.
Enen Chen *The Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China.
Jianfen Su *The Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China.
Yingjie Gong *The Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China.
Shiqi TangThe Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China.
Aiping QinThe Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China.
Ao ShenThe Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China. shenao@gzhmu.edu.cn.
Shunqing TangDepartment of Biomedical Engineering, Jinan University, Guangzhou, 510632, China. tshunqt@jnu.edu.cn.
Lingmin ZhangThe Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, P. R. China. zhanglm@gzhmu.edu.cn.

Funding

National Natural Science Foundation of China 32171312National Natural Science Foundation of China 82072047National Natural Science Foundation of China 82170008
6 · The paper itself

Abstract

introductionAcute lung injury (ALI) is an acute inflammatory lung disease with high rates of morbidity and mortality. The lack of efficient pharmacological treatments for ALI resulted in poor outcomes and prognosis.

methodsPoly(lactic-co-glycolic acid) (PLGA) was used to carry magnetic nanoparticles and TRIM24-targeted PROTAC (dTRIM24), which was further camouflaged with the exosome membranes derived from M1 macrophages to obtain nano-PROTAC (EM/PLGA/Magnetic nanoparticles/dTRIM24, EMPLANT). We evaluated the nanoparticles on the physicochemical properties, cellular uptake, in vitro toxicity, anti-inflammatory effects, in vivo biodistribution, in vivo therapeutic effect, anti-inflammatory capacity, and in vivo safety.

resultsThis nano-PROTAC EMPLANT, shows dual-targeting capability by magnetic navigation and inflammatory specificity. EMPLANT selectively accumulates in the inflammatory lungs in ALI model mice under an external magnetic field, reduces lung injuries, and drastically prolongs survival. Mechanistically, the degradation of TRIM24 upregulates the expression of STAT6 and thus promotes an efficient phenotypic switch of macrophages from M1 to M2. This strategy can ameliorate ALI greatly and increase the survival ratio to nearly 100%.

conclusionThe nano-PROTAC demonstrates a promising therapeutic strategy for ALI through precisely in situ reprogramming macrophages. To the best of our knowledge, we are the first to develop this type of magnetically navigated artificial exosomes to deliver PROTAC and use it for ALI treatment.

Indexed as

Acute Lung InjuryMagnetite NanoparticlesAnimalsAnti-Inflammatory AgentsDisease Models, AnimalExosomesHumansMacrophagesMaleMiceMice, Inbred C57BLPolylactic Acid-Polyglycolic Acid CopolymerRAW 264.7 CellsTissue DistributionAnti-Inflammatory AgentsMagnetite NanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerAcute lung injuryMacrophage polarizationMagnetic navigationPROTACPulmonary inflammation

Identifiers

PMID41034872
PMCPMC12486976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.